InSite obtains rights to optineurin gene

Article

A test for the optineurin gene will be available to ophthalmologists soon - possibly this year and certainly by 2003, said S. Kumar Chandrasekaran, PhD, CEO of InSite Vision, Alameda, CA.

Recent Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
Promising results for faricimab revealed in TENAYA, LUCERNE year 2 data
Orbis in-person training takes flight once again
Elkin: Talking about the importance of pediatric eye health and safety
Related Content
What ophthalmologists need to know about neuromyelitis optica spectrum disorder

What ophthalmologists need to know about neuromyelitis optica spectrum disorder

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Podcast
FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO

FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO

Article
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics

Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention

Podcast
Beacon Therapeutics treats first patient in VISTA registrational trial for AGTC-501

Beacon Therapeutics treats first patient in VISTA registrational trial for AGTC-501

Article
Pegcetacoplan injection preserves visual function at 36 weeks in patients with geographic atrophy

Pegcetacoplan injection preserves visual function at 36 weeks in patients with geographic atrophy

Article
© 2024 MJH Life Sciences

All rights reserved.